Developmental and reproduction toxicity of piperonyl butoxide part 2 developmental safety of piperonyl butoxide in the NZW rabbit.


Journal

Reproductive toxicology (Elmsford, N.Y.)
ISSN: 1873-1708
Titre abrégé: Reprod Toxicol
Pays: United States
ID NLM: 8803591

Informations de publication

Date de publication:
09 2022
Historique:
received: 16 06 2022
revised: 28 07 2022
accepted: 31 07 2022
pubmed: 6 8 2022
medline: 24 8 2022
entrez: 5 8 2022
Statut: ppublish

Résumé

Piperonyl butoxide (PBO) was developed in the 1940s. PBO increases the effectiveness of pyrethrins, thus it is called a synergist. Herein, the findings from a guideline developmental toxicity study in rabbits conducted in 1986 are reported. Inseminated New Zealand White rabbits were randomly assigned to a control and three treatment groups of 16 does each. Dose levels of 50, 100 and 200 mg/kg/day were selected based on a dosage-range study to avoid excessive maternal toxicity and administered orally (gavage) as a single daily dose on days 7-19 of gestation at a volume of 0.5 mL/kg. The control group received the vehicle only, Mazola® corn oil. Cesarean sections were performed on all surviving females on gestation day 29 and fetuses were evaluated. Survival for all study groups was 100%. Treatment-related maternotoxicity was manifested at the 100 and 200 mg/kg/day levels as decreased defecation and dose-related body weight losses during the treatment period (gestation days 7-13 and 7-19). The Cesarean section parameter values and fetal morphological observations of the treated groups did not differ significantly from the concurrent control group and were within the historical control range for this rabbit strain. No maternal or fetal adverse effects were seen at the 50 mg/kg/day dose level. Although maternal toxicity resulting from treatment was apparent at the 100 and 200 mg/kg/day dose levels, neither fetotoxicity nor teratogenicity were elicited in rabbits by piperonyl butoxide at dose levels as high as 200 mg/kg/day.

Identifiants

pubmed: 35931401
pii: S0890-6238(22)00115-0
doi: 10.1016/j.reprotox.2022.07.009
pii:
doi:

Substances chimiques

Pyrethrins 0
Piperonyl Butoxide LWK91TU9AH

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

177-181

Informations de copyright

Copyright © 2022 Elsevier Inc. All rights reserved.

Auteurs

Alan M Hoberman (AM)

Charles River Laboratories, Inc, 905 Sheehy Dr., Horsham, PA 19044, United States. Electronic address: alan.hoberman@crl.com.

Judith W Hauswirth (JW)

Hauswirth Consulting, Inc, 3222 Green Forest Ct., Ellicott City, MD 21042, United States. Electronic address: jhaus7810@yahoo.com.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH